Updated:
Locust Walk Acquisition Corp.
Locust Walk Acquisition Corp. was established as a SPAC-formation arm of Locust Walk Partners, a global life science investment bank and strategy...
Locust Walk Acquisition Corp.
Locust Walk Acquisition Corp. was established as a SPAC-formation arm of Locust Walk Partners, a global life science investment bank and strategy consulting firm. Chris Ehrlich, its CEO, came to the role from InterWest Partners, a venture capital firm, and earlier held senior business development posts in the life sciences (per firm website). The firm's mandate is to lead the formation and capital raising of independent SPACs that target mergers with one or more businesses in biopharma and medtech. It does not disclose a portfolio of completed deals, nor does it publish AUM. The SPAC structure gives Locust Walk Acquisition Corp. a specific vehicle-driven focus rather than a traditional family office allocation approach. Locust Walk Acquisition Corp. operates across a multi-office footprint including Menlo Park, Boston, San Diego, New York, London, and San Francisco. Its Scientific Advisory Board includes prominent names in drug development and oncology: Jeremy Goldberg (Arsenal Capital Partners), Ross Levine (Memorial Sloan Kettering), and Merit Cudkowicz (Mass General). In the last 24 months, no completed SPAC merger has been publicly announced as of May 2026 (per firm website). The firm's structural differentiator is its integration with Locust Walk Partners' investment banking and strategy consulting platform — allowing sponsors to originate deals through an existing life science transaction network rather than operating as a standalone SPAC issuer. This creates a sourcing advantage that pure-play SPAC sponsors typically lack.
General information
Firm type
Single Family Office
Year founded
—
AUM
Undisclosed
Location
Region
North America
Country
United States
City
Menlo Park
Corporate office
Menlo Park, CA, United States
Additional offices
Pasadena · Boston · Bala Cynwyd · San Diego · New York · Kirkland · Wayne · London · San Francisco · Montreal
Principals
Chris Ehrlich
Chief Executive Officer, Director
Dan Geffken
Chief Financial Officer
Brian Atwood
Chairman
Sector focus
Frequently asked questions
Who runs investment decisions at Locust Walk Acquisition Corp.?
Chris Ehrlich serves as CEO and Director, with background as a Managing Director at InterWest Partners and senior business development roles in life sciences. Dan Geffken is CFO, and Brian Atwood (Managing Director at Versant Ventures) is Chairman. A Scientific Advisory Board led by Jeremy Goldberg provides deal evaluation support (per firm website).
Is Locust Walk Acquisition Corp. structured as a single family office or does it operate more like a venture firm?
It is not a family office. It is a SPAC-formation vehicle sponsored by Locust Walk Partners, a life science investment bank. The firm's purpose is to raise capital through IPOs and execute de-SPAC mergers in life sciences, not to manage ongoing investment portfolios.
How does Locust Walk Acquisition Corp. source proprietary deal flow?
The firm draws on the network and transaction expertise of Locust Walk Partners, which integrates investment banking and strategy consulting for life science companies. The Scientific Advisory Board provides additional deal-sourcing channels through members' roles at top institutions (Memorial Sloan Kettering, Mass General, Bayer, Genentech) (per firm website).
Does Locust Walk Acquisition Corp. participate in fund commitments or only direct deals?
The firm operates only through direct SPAC mergers. It does not invest in external funds or make venture capital commitments. Its capital structure is focused on the SPAC vehicle and its merger target.
What investment stages does Locust Walk Acquisition Corp. typically target?
The firm targets merger candidates across biopharma and medtech at any stage that would benefit from a public listing via de-SPAC. The website does not specify a revenue or clinical-stage preference.
Where does the underlying wealth come from?
Not publicly disclosed. The firm does not identify a single underlying family or fortune. It is a SPAC vehicle sponsored by Locust Walk Partners, a corporate entity, rather than a family office managing private wealth.
Does Locust Walk maintain philanthropic structures, and how are they separated?
The firm does not disclose any philanthropic foundation or charitable arm. As a for-profit SPAC issuer, there is no separate philanthropic entity tied to Locust Walk Acquisition Corp.
Profile maintained by Altss using OSINT (open-source intelligence), regulatory filings, licensed data partners, and verified direct submissions. Read the methodology. Last updated: . Continuous refresh with full update cycles at least every 30 days.
Need institutional-grade insight on family offices?
Altss delivers:
Prefer a guided tour?
We’ll walk you through: